Preferred Label : oximes;

MeSH definition : Compounds that contain the radical R2C N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.;

MeSH synonym : compounds, hydroxyimino; hydroxyimino compounds; Oxime;

MeSH hyponym : ketoximes; aldoximes; Ketoxime;

Wikipedia link : https://en.wikipedia.org/wiki/Oxime;

Is substance : O;

Details


Main resources

You can consult :

Compounds that contain the radical R2C N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.

https://www.has-sante.fr/jcms/p_3146424/fr/tafinlar-mekinist
2020
false
false
false
France
BRAF V600E mutation positive
dabrafenib
dabrafenib
treatment outcome
antineoplastic combined chemotherapy protocols
trametinib
antineoplastic agents
protein kinase inhibitors
trametinib
carcinoma, non-small-cell lung
BRAF protein, human
evaluation of the transparency committee
imidazoles
oximes
pyridones
pyrimidinones
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/portail/jcms/c_2967190/fr/tafinlar
2019
true
France
French
administration, oral
insurance, health, reimbursement
dabrafenib
dabrafenib
dabrafenib
adult
melanoma
antineoplastic agents
antineoplastic agents
BRAF protein, human
evaluation of the transparency committee
neoplasm metastasis
treatment outcome
mutation
survival analysis
Unresectable
BRAF V600E Mutation Present
BRAF V600K Mutation Present
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/portail/jcms/c_2911595/fr/mekinist-tafinlar
2019
false
true
false
false
France
trametinib
dabrafenib
treatment outcome
melanoma
administration, oral
antineoplastic combined chemotherapy protocols
adult
antineoplastic agents
protein kinase inhibitors
melanoma
BRAF V600 Mutation
evaluation of the transparency committee
pyridones
pyrimidinones
imidazoles
oximes

---
https://www.has-sante.fr/portail/jcms/c_2835407/fr/mekinist-tafinlar
https://www.has-sante.fr/portail/jcms/c_2835407/fr/tafinlar-dabrafenib-en-association-a-mekinist-trametinib-inhibiteurs-de-la-proteine-kinase
2018
false
false
false
false
France
French
evaluation of the transparency committee
dabrafenib
dabrafenib
antineoplastic combined chemotherapy protocols
treatment outcome
administration, oral
carcinoma, non-small-cell lung
BRAF V600 Mutation
trametinib
trametinib
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
guidelines for drug use
pyridones
pyrimidinones
pyridones
pyrimidinones
imidazoles
oximes
imidazoles
oximes

---
http://www.cochrane.org/fr/CD010770/medicaments-pour-traiter-les-fibromes
2017
false
false
false
France
United Kingdom
French
french abstract
premenopause
fibroid uterus
Evidence-Based medicine
treatment outcome
progesterone receptor modulators
review of literature
mifepristone
ulipristal acetate
comparative effectiveness research
asoprisnil
leuprolide acetate
receptors, progesterone
leiomyoma
leuprolide
norpregnadienes
estrenes
oximes

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BRAF-en-monotherapie-vemurafenib-dabrafenib-Medicaments-ciblant-BRAF-ou-MEK-en-association-vemurafenib-cobimetinib-dabrafenib-trametinib
2016
false
false
false
France
French
guidelines for drug use
practice guideline
patients guideline
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
administration, oral
drug interactions
vemurafenib
vemurafenib
antineoplastic combined chemotherapy protocols
vemurafenib
dabrafenib
dabrafenib
dabrafenib
BRAF protein, human
Metastatic Melanoma
melanoma
melanoma
neoplasm metastasis
BRAF Gene Mutation
continuity of patient care
drug monitoring
interdisciplinary communication
protein kinase inhibitors
vemurafenib
dabrafenib
pregnancy
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf
imidazoles
oximes
indoles
sulfonamides
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_1742463/fr/tafinlar
2014
false
France
French
administration, oral
insurance, health, reimbursement
dabrafenib
dabrafenib
dabrafenib
adult
melanoma
antineoplastic agents
antineoplastic agents
BRAF protein, human
evaluation of the transparency committee
neoplasm metastasis
treatment outcome
mutation
survival analysis
Unresectable
BRAF V600E Mutation Present
BRAF V600K Mutation Present
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf

---
http://www.meddispar.fr/index.php/Medicaments/TAFINLAR-75-B-120/
2014
false
false
false
France
French
drug information
dabrafenib
dabrafenib
administration, oral
legislation, drug
drug prescriptions
continuity of patient care
capsules
imidazoles
oximes

---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20257
France
French
butanones
butanones
oximes
oximes
butanones
butanones
butanones
oximes
oximes
oximes
occupational exposure
occupational diseases
reference values
2-butanone oxime
guidelines
toxicological data sheet

---
http://www.cochrane.org/fr/CD005085
2011
United Kingdom
France
French
meta-analysis
organophosphate poisoning
pesticides
oximes
treatment outcome
Organophosphate pesticides
environmental pollutants
french abstract

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.